Methylphenidate Hydrochloride Tablet, Extended Release shortage
Current 34 presentations · 6 manufacturers · first FDA posting 2023-07-26 · last update 2026-10-15
Manufacturers: Janssen Pharmaceuticals, Lannett Company, Inc., Sun Pharmaceutical Industries, Inc., Teva Pharmaceuticals USA, Inc., Trigen Laboratories, LLC, Vertical Pharmaceuticals, LLC
Stated reasons (per FDA): Demand increase for the drug; Discontinuation of the manufacture of the drug; Other
Presentations
| Presentation | Manufacturer | Status | Reason | Notes (FDA) | Dates |
|---|---|---|---|---|---|
| Concerta, Tablet, Extended Release, 18 mg (NDC 50458-585-01) | Janssen Pharmaceuticals | Current Available |
— | Posted 07/26/2023 Updated 09/17/2026 | |
| Concerta, Tablet, Extended Release, 36 mg (NDC 50458-586-01) | Janssen Pharmaceuticals | Current Available |
— | Posted 07/26/2023 Updated 09/17/2026 | |
| Concerta, Tablet, Extended Release, 54 mg (NDC 50458-587-01) | Janssen Pharmaceuticals | Current Available |
— | Posted 07/26/2023 Updated 09/17/2026 | |
| Concerta, Tablet, Extended Release, 27 mg (NDC 50458-588-01) | Janssen Pharmaceuticals | Current Available |
— | Posted 07/26/2023 Updated 09/17/2026 | |
| Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 62175-310-37) | Lannett Company, Inc. | Current Available |
— | Posted 07/26/2023 Updated 10/15/2026 | |
| Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 62175-311-37) | Lannett Company, Inc. | Current Unavailable |
Other | Estimated recovery: November 2026 | Posted 07/26/2023 Updated 10/15/2026 |
| Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 62175-312-37) | Lannett Company, Inc. | Current Unavailable |
Other | Estimated recovery: November 2026 | Posted 07/26/2023 Updated 10/15/2026 |
| Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 62175-313-37) | Lannett Company, Inc. | Current Available |
— | Posted 07/26/2023 Updated 10/15/2026 | |
| Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 57664-606-88) | Sun Pharmaceutical Industries, Inc. | Current Unavailable |
Discontinuation of the manufacture of the drug | Currently not marketed | Posted 07/26/2023 Updated 09/18/2026 |
| Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 57664-607-88) | Sun Pharmaceutical Industries, Inc. | Current Unavailable |
Discontinuation of the manufacture of the drug | Currently not marketed | Posted 07/26/2023 Updated 09/18/2026 |
| Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 57664-608-88) | Sun Pharmaceutical Industries, Inc. | Current Unavailable |
Discontinuation of the manufacture of the drug | Currently not marketed | Posted 07/26/2023 Updated 09/18/2026 |
| Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 57664-609-88) | Sun Pharmaceutical Industries, Inc. | Current Unavailable |
Discontinuation of the manufacture of the drug | Currently not marketed | Posted 07/26/2023 Updated 09/18/2026 |
| Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 62037-725-01) | Teva Pharmaceuticals USA, Inc. | Current Limited Availability |
Other | Estimated recovery: October 2026 | Posted 07/26/2023 Updated 10/01/2026 |
| Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 62037-726-01) | Teva Pharmaceuticals USA, Inc. | Current Limited Availability |
Other | Estimated recovery: October 2026 | Posted 07/26/2023 Updated 10/15/2026 |
| Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 62037-727-01) | Teva Pharmaceuticals USA, Inc. | Current Available |
— | Posted 07/26/2023 Updated 10/15/2026 | |
| Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 62037-734-01) | Teva Pharmaceuticals USA, Inc. | Current Available |
— | Posted 07/26/2023 Updated 10/01/2026 | |
| Methylphenidate Hydrochloride, Tablet, Extended Release, 63 mg (NDC 13811-700-30) | Trigen Laboratories, LLC | Current Limited Availability |
Demand increase for the drug | Allocation to current contracted customers | Posted 07/26/2023 Updated 10/01/2026 |
| Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 13811-706-10) | Trigen Laboratories, LLC | Current Limited Availability |
Demand increase for the drug | Allocation to current contracted customers | Posted 07/26/2023 Updated 10/01/2026 |
| Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 13811-707-10) | Trigen Laboratories, LLC | Current Limited Availability |
Demand increase for the drug | Allocation to current contracted customers | Posted 07/26/2023 Updated 10/01/2026 |
| Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 13811-708-10) | Trigen Laboratories, LLC | Current Limited Availability |
Demand increase for the drug | Allocation to current contracted customers | Posted 07/26/2023 Updated 10/01/2026 |
| Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 13811-709-10) | Trigen Laboratories, LLC | Current Limited Availability |
Demand increase for the drug | Allocation to current contracted customers | Posted 07/26/2023 Updated 10/01/2026 |
| Methylphenidate Hydrochloride, Tablet, Extended Release, 72 mg (NDC 13811-710-30) | Trigen Laboratories, LLC | Current Limited Availability |
Demand increase for the drug | Allocation to current contracted customers | Posted 07/26/2023 Updated 10/01/2026 |
| Methylphenidate Hydrochloride, Tablet, Extended Release, 45 mg (NDC 13811-711-30) | Trigen Laboratories, LLC | Current Limited Availability |
Demand increase for the drug | Allocation to current contracted customers | Posted 07/26/2023 Updated 10/01/2026 |
| Relexxii, Tablet, Extended Release, 72 mg (NDC 68025-084-30) | Vertical Pharmaceuticals, LLC | Current Available |
— | Posted 07/26/2023 Updated 10/01/2026 | |
| Relexxii, Tablet, Extended Release, 45 mg (NDC 68025-088-30) | Vertical Pharmaceuticals, LLC | Current Available |
— | Posted 07/26/2023 Updated 10/01/2026 | |
| Relexxii, Tablet, Extended Release, 63 mg (NDC 68025-089-30) | Vertical Pharmaceuticals, LLC | Current Available |
— | Posted 07/26/2023 Updated 10/01/2026 | |
| Relexxii, Tablet, Extended Release, 18 mg (NDC 68025-095-10) | Vertical Pharmaceuticals, LLC | Current Available |
— | Posted 07/26/2023 Updated 10/01/2026 | |
| Relexxii, Tablet, Extended Release, 18 mg (NDC 68025-095-30) | Vertical Pharmaceuticals, LLC | Current Available |
— | Posted 07/26/2023 Updated 10/01/2026 | |
| Relexxii, Tablet, Extended Release, 27 mg (NDC 68025-096-10) | Vertical Pharmaceuticals, LLC | Current Available |
— | Posted 07/26/2023 Updated 10/01/2026 | |
| Relexxii, Tablet, Extended Release, 27 mg (NDC 68025-096-30) | Vertical Pharmaceuticals, LLC | Current Available |
— | Posted 07/26/2023 Updated 10/01/2026 | |
| Relexxii, Tablet, Extended Release, 36 mg (NDC 68025-097-10) | Vertical Pharmaceuticals, LLC | Current Available |
— | Posted 07/26/2023 Updated 10/01/2026 | |
| Relexxii, Tablet, Extended Release, 36 mg (NDC 68025-097-30) | Vertical Pharmaceuticals, LLC | Current Available |
— | Posted 07/26/2023 Updated 10/01/2026 | |
| Relexxii, Tablet, Extended Release, 54 mg (NDC 68025-098-10) | Vertical Pharmaceuticals, LLC | Current Available |
— | Posted 07/26/2023 Updated 10/01/2026 | |
| Relexxii, Tablet, Extended Release, 54 mg (NDC 68025-098-30) | Vertical Pharmaceuticals, LLC | Current Available |
— | Posted 07/26/2023 Updated 10/01/2026 |
Get the weekly shortage roundup: a free email of FDA shortage changes (open form)